Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations

Respiratory Medicine

Volumn 109, Issue 7, 2015, Pages 870-881

  Donohue, James F ^a   Worsley, Sally ^b   Zhu, Chang Qing ^c   Hardaker, Liz ^c   Church, Alison ^d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b GSK Respiratory Medicines Development Centre   (United Kingdom)

^c GLAXOSMITHKLINE   (United Kingdom)

^d GLAXOSMITHKLINE   (United States)

Author keywords

COPD; Fluticasone propionate; Salmeterol; Umeclidinium; Vilanterol

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; UMECLIDINIUM PLUS VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE; VILANTEROL;

ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INSPIRATORY CAPACITY; INTENTION TO TREAT ANALYSIS; LOWER RESPIRATORY TRACT INFECTION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MORNING DOSAGE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE ASSESSMENT; RHINOPHARYNGITIS; SCORING SYSTEM; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TRANSITION DYSPNEA INDEX FOCAL SCORE; AGED; CLINICAL TRIAL; DRUG EFFECTS; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOUBLE-BLIND METHOD; FEMALE; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84930758390     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2015.04.018     Document Type: Article

References (25)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2014 http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html [Date last accessed: 23 September 2014]
2. Y. Oba, and N.A. Lone Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis Int J Chron Obstruct Pulmon Dis 9 2014 469 479
3. S. Singh, and Y.K. Loke An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 5 2010 189 195
4. K.M. Kew, and A. Seniukovich Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease Cochrane Database Syst Rev 3 2014 CD010115
5. J. Vestbo, C. Vogelmeier, M. Small, and V. Higgins Understanding the GOLD 2011 strategy as applied to a real-world COPD population Respir Med 108 2014 729 736
6. ANORO US prescribing information May 2014 Available at http://www.gsksource.com/gskprm/htdocs/documents/ANORO-ELLIPTA-PI-MG.PDF [Date last accessed: 23 September 2014]
7. Anoro EU summary of product characteristics 16 May 2014 Available at http://www.medicines.ie/medicine/16007/SPC/ANORO+55+micrograms+22+micrograms+inhalation+powder+pre-dispensed/. [Date last accessed: 23 September 2014]
8. B. Celli, G. Crater, and S. Kilbride Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study Chest 145 2014 981 991
9. J.F. Donohue, M.R. Maleki-Yazdi, S. Kilbride, R. Mehta, C. Kalberg, and A. Church Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD Respir Med 107 2013 1538 1546
10. M. Decramer, A. Anzueto, and E. Kerwin Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials Lancet Respir Med 2 2014 472 486
11. J. Donohue, D. Niewoehner, J. Brooks, D. O'Dell, and A. Church Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study Respir Res 15 2014 78
12. ADVAIR DISKUS US prescribing information May 2014 Available at http://www.advair.com/. [Date last accessed: 23 September 2014]
13. N.A. Hanania, P. Darken, and D. Horstman The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD Chest 124 2003 834 843
14. G.T. Ferguson, A. Anzueto, R. Fei, A. Emmett, K. Knobil, and C. Kalberg Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations Respir Med 102 2008 1099 1108
15. A. Anzueto, G.T. Ferguson, and G. Feldman Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes COPD 6 2009 320 329
16. D. Singh, S. Worsley, C.-Q. Zhu, L. Hardaker, and A. Church Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations Eur Respir J 44 Suppl. 56 2014 290 [abstract]
17. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013 World medical association declaration of Helsinki - ethical principles for medical research involving human subjects October 2008 http://www.wma.net/en/30publications/10policies/b3/index.html [Date last accessed: 23 September 2014]
18. International conference on harmonisation tripartite guideline: guidance for good clinical practice E6 (R1). http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf [Date last accessed: 11 August 2014].
19. A. Agusti, P.M. Calverley, and B. Celli Characterisation of COPD heterogeneity in the ECLIPSE cohort Respir Res 11 2010 122
20. R.D. Yusen Evolution of the GOLD documents for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Controversies and questions Am J Respir Crit Care Med 188 2013 4 5
21. K.F. Rabe, W. Timmer, A. Sagkriotis, and K. Viel Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD Chest 134 2008 255 262
22. C.F. Vogelmeier, E.D. Bateman, and J. Pallante Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study Lancet Respir Med 1 2013 51 60
23. M. Thomas, M. Decramer, and D.E. O'Donnell No room to breathe: the importance of lung hyperinflation in COPD Prim Care Respir J 22 2013 101 111
24. J.A. Guenette, K.A. Webb, and D.E. O'Donnell Effect of fluticasone/salmeterol combination on dyspnea and respiratory mechanics in mild-to-moderate COPD Respir Med 107 2013 708 716
25. D.E. O'Donnell, F. Sciurba, and B. Celli Effect of fluticasone propionate on lung hyperinflation and exercise endurance in COPD Chest 130 2006 647 656